PI3K inhibitor ZSTK474 enhancing the antitumor of vesicular stomatitis virus A51 against osteosarcoma
10.16098/j.issn.0529-1356.2022.04.013
- Author:
Li-Zhu LIU
1
;
Chao-Yi LI
1
;
Shi-Wei LIN
1
;
Ye QU
1
;
Qiang TANG
2
Author Information
1. Department ofTrauma Surgery, The Second Affiliated Hospital of Hainan Medical College
2. Hainan Key Laboratory of Oncology and Intervention, Hainan Medical College
- Publication Type:Journal Article
- Keywords:
Mouse;
Oncolytic virus;
Osteosarcoma;
Phosphatidylinositol 3-kinase inhibitor;
Vesicular stomatitis virus A51;
Western blotting
- From:
Acta Anatomica Sinica
2022;53(4):498-506
- CountryChina
- Language:Chinese
-
Abstract:
Objective To explore whether PI3K inhibitor combined with oncolytic virus can play an effective oncolytic effect on osteosarcoma. Methods The cytotoxicity to tumor cells was detected by MTT method, and the mechanism of enhancing the anti-tumor activity was explored by observation of the swelling of endoplasmic reticulum using electron microscope and the expression of apoptosis-related proteins using Western blotting. The tumor clearance ability of the combination of the PI3k inhibitor ZSTK474 and vesicular stomatitis virus A51 (VSVA51) was verified by anti-tumor experiment in vivo. The apoptosis of tumor cells was verified by immunohistochemistry. Results PI3K inhibitor could be used as sensitizers of oncolytic VSVA51, and confirmed that the)' promoted the strong apoptosis of osteosarcoma cells by aggravating the stress of endoplasmic reticulum in tumor cells (P < 0 . 01). In vivo experiments also showed that PI3K inhibitors combined with VSVA51 could significantly promote the oncolytic effect of osteosarcoma (P<0.001), and this combination therapy enhanced the infiltration of immune cells in the tumor (P<0.001). Conclusion PI3K inhibitors combined with oncolytic virus is a potential therapy for osteosarcoma.
